At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Copanlisib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
In Brief
A Phase 2 clinical trial evaluating Copanlisib and Laboratory Biomarker Analysis for Endometrial Endometrioid Adenocarcinoma and 5 related conditions. Completed, enrolled 11 participants across 43 sites.
Detailed Summary
This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Metastatic Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartSep 2016
Primary CompletionAug 2018
Study CompletionFeb 2020
TodayJul 2026
First PostedApr 5, 2016
Enrollment StartSep 16, 2016
Primary CompletionAug 18, 2018
Study CompletionFeb 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.2 years ago
Interventions
Copanlisibdrug
Given IV
Laboratory Biomarker Analysisother
Correlative studies